百特醫療 (BAX) 2016 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to Baxter International's first-quarter 2016 earnings conference call.

    歡迎參加百特國際(Baxter International)2016 年第一季財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本次電話會議由百特錄音,並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請於此時掛線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations, at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話會議交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • - VP of IR

    - VP of IR

  • Thanks, Candace.

    謝謝你,Candace。

  • Good morning and welcome to our first-quarter 2016 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    各位早安,歡迎參加我們 2016 年第一季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's first-quarter financial results and updated outlook for 2016, before taking your questions. I would just like to remind you that during the Q&A session, if you could please limit yourself to one question and one follow-up, so we can accommodate others in the queue.

    今天早上的電話會議中,我們將在回答各位提問之前,先討論百特第一季財務結果以及 2016 年最新展望。也提醒各位,在問答環節中,請盡量每人一個問題並加上一個追問,以便我們能讓隊列中的其他人也有機會提問。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, and regulatory matters contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.

    接下來,我先以預先準備的發言開場,提醒各位本簡報(包括關於我們財務展望、新產品開發及法規事項的評論)包含前瞻性陳述,並涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期出現重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更多細節。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續經營的業務表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標之調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站查閱。

  • Before I turn the call over to Joe, I would like to remind everyone that we will be hosting an Investor Conference on May 9 in New York City. At the conference, we will be providing an update on our strategic and financial aspirations, along with showcasing our innovative new product pipeline at an innovation fair. More details, along with the link to register for the event, can be found on the Investor Relations section of our website.

    在我把電話交給 Joe 之前,我想提醒各位,我們將於 5 月 9 日在紐約市舉辦投資人會議。在會議上,我們將更新我們的策略與財務目標,並在創新展中展示我們具創新性的新品研發管線。更多細節以及活動報名連結,可在我們網站的投資人關係專區找到。

  • Now I'd like to turn the call over to Joe. Joe?

    現在我想把電話交給 Joe。Joe?

  • - Chairman and CEO

    - Chairman and CEO

  • Good morning, everyone, and thanks, Clare.

    各位早安,謝謝你,Clare。

  • As you saw in our press release this morning, we reported a strong first quarter, with both the top-line and bottom-line results exceeding our expectations. I will provide some brief comments on performance before turning it over to Jay for additional details and an update on our full-year outlook. After that, we will open the call for Q&A. So let's get started.

    如各位今早在我們的新聞稿中所見,我們第一季表現強勁,營收與獲利皆超出我們的預期。在把電話交給 Jay 提供更多細節並更新我們全年展望之前,我會先就表現做一些簡短評論。之後我們將開放問答。那我們開始吧。

  • Worldwide sales grew 4% on constant-currency basis and decreased 1% on a reported basis. Operational growth was at the high end of our guidance, and we're pleased with the sequential quarterly improvement in sales growth for total Baxter, within both the Renal and Hospital Products segments.

    以固定匯率計算,全球銷售成長 4%;以報告基礎計算則下降 1%。營運成長位於我們指引區間的高端,我們也對百特整體(包含腎臟與醫院產品兩大事業部)銷售成長在季度間的連續改善感到滿意。

  • Sales growth was primarily driven by strength in the US fluid systems and PD businesses, along with strong performance in acute renal therapies. They delivered adjusted earnings of $0.36 per diluted share, exceeding our guidance range of $0.28 to $0.30 per diluted share. These results reflect a positive sales mix, continued spending discipline, and some favorability from foreign exchange versus previous guidance.

    銷售成長主要由美國輸液系統與腹膜透析(PD)業務的強勁表現所帶動,並加上急性腎臟治療的亮眼成果。調整後每股稀釋盈餘為 0.36 美元,超出我們每股稀釋盈餘 0.28 至 0.30 美元的指引區間。這些結果反映了有利的銷售組合、持續的費用紀律,以及相較先前指引外匯帶來的部分利多。

  • Let me summarize performance by franchise. Please note that I will be speaking to sales growth on a constant-currency basis, excluding any foreign exchange impact for each of the businesses and franchise, to provide a clearer picture of Baxter's underlying operational performance.

    我先按產品線(franchise)總結表現。請注意,為了更清楚呈現百特的核心營運表現,我將以固定匯率基礎說明各業務與產品線的銷售成長,並排除外匯對各業務與產品線的影響。

  • Starting with Hospital Products, global sales totaled $1.5 billion, and increased 4%. As planned, first-quarter sales of US cyclophosphamide totaled $60 million and were similar to the prior period. As a result, sales of cyclophosphamide did not impact the growth rate for the quarter.

    先從醫院產品(Hospital Products)開始,全球銷售額合計 15 億美元,成長 4%。如規劃所示,第一季美國環磷醯胺(cyclophosphamide)銷售額為 6,000 萬美元,與前期相近。因此,環磷醯胺的銷售並未影響本季的成長率。

  • Within the fluid systems franchise, sales totaled $524 million, up 11%; growth in the franchise was driven by strength in the US, supported by the continued successful launch of the SIGMA Spectrum infusion pump, as well as favorable price and demand for IV solutions in the US. We have successfully renegotiated all of our large GPO contracts, including the recent agreement with HealthTrust. This contract is built upon our partnership with US customers that will ultimately allow us to serve more patients, and position Baxter for continued growth.

    在輸液系統(fluid systems)產品線中,銷售額合計 5.24 億美元,成長 11%;成長主要由美國市場的強勁表現所帶動,並受惠於 SIGMA Spectrum 輸注幫浦持續成功上市,以及美國靜脈注射(IV)溶液的有利價格與需求。我們已成功重新談判所有大型團體採購組織(GPO)合約,包括近期與 HealthTrust 的協議。此合約建立在我們與美國客戶的合作夥伴關係之上,最終將使我們能服務更多病患,並讓百特具備持續成長的有利定位。

  • Sales in the integrative pharmacy solutions franchise totaled $556 million, an increase of 3%. After adjusting revenues for a government preparedness for last year, sales in the category increased 6%.

    整合式藥局解決方案(integrative pharmacy solutions)產品線銷售額合計 5.56 億美元,成長 3%。若將去年政府備援準備(government preparedness)相關收入調整後,該類別銷售成長為 6%。

  • Growth was driven by strength across the franchise, including nutritional products, pharmacy injectables, and hospital pharmacy compounding services. This category also includes cyclophosphamide, which, as planned, did not impact growth in the quarter.

    成長動能來自整個產品線的強勁表現,包括營養產品、藥局注射劑,以及醫院藥局調配服務。此類別亦包含環磷醯胺;如規劃所示,其並未影響本季成長。

  • Key to growth in our IPS business is broadening our product offering. Last week we launched VANCOMYCIN saline in the Company's proprietary GALAXY flexible container, which enables unstable molecules to be pre-mixed, and ensures [sterility] and operational efficiency at the point of care. VANCOMYCIN saline is the second of nine molecules that we will be introducing -- rather, we will be introducing over the next few years, and we recently submitted our third molecule for review with the FDA.

    推動我們 IPS 業務成長的關鍵,在於擴大我們的產品供應。上週我們在公司專有的 GALAXY 軟式容器中推出 VANCOMYCIN 生理食鹽水,讓不穩定分子得以預先混合,並在照護現場確保[無菌]與作業效率。VANCOMYCIN 生理食鹽水是我們九種分子中的第二個——更確切地說,我們將在未來幾年陸續推出;而我們近期也已向 FDA 提交第三種分子以供審查。

  • We also continue to expand our nutrition portfolio globally, and recently announced the approval of our NUMETA G13 in the UK and Denmark. This markets represent the first of 20 countries where we look to launch this year. NUMETA G13 is a triple-chamber parenteral nutrition product focused on meeting the specialized needs of pre-term infants. Expanding the formulations of NUMETA will help address an underserved market segment.

    我們也持續在全球擴展營養產品組合,並於近期宣布 NUMETA G13 已在英國與丹麥獲准。這些市場代表我們今年預計推出的 20 個國家中的首批。NUMETA G13 是一款三腔室腸外營養產品,著重滿足早產兒的特殊需求。擴充 NUMETA 的配方將有助於滿足一個供給不足的市場區隔。

  • Within surgical care, which includes our anesthesia and biosurgery products, first-quarter revenues totaled $305 million, declining 2%. Sales in the quarter were impacted by lower sales of selected non-core biosurgery products and weaker-than-expected international biosurgery sales. Partially offsetting this impact was mid-single-digit growth of both US surgical sealant and hemostasis products, as well as international anesthesia products, where we continue to expand the market and capture share. Baxter is now the market leader globally for inhaled aesthetics.

    在外科照護(surgical care)方面(包含我們的麻醉與生物外科產品),第一季營收合計 3.05 億美元,下降 2%。本季銷售受到部分非核心生物外科產品銷售下滑,以及國際生物外科銷售弱於預期的影響。部分抵銷上述影響的是:美國外科封合劑與止血產品皆有中個位數成長,以及國際麻醉產品的成長;我們持續擴大市場並提升市占。百特目前已是全球吸入式麻醉藥市場的領導者。

  • surgical care remains an attractive area, and we are prepared to accelerate the performance through innovation. In the first quarter, we received approvals for expanded indications for HEMOPATCH in the EU and FLOSEAL in Japan. Both offer great utility among surgeons using these hemostatic agents.

    外科照護仍是具吸引力的領域,我們已準備透過創新加速提升表現。第一季,我們取得 HEMOPATCH 在歐盟的適應症擴大核准,以及 FLOSEAL 在日本的核准。對於使用這些止血劑的外科醫師而言,兩者都具有很高的實用性。

  • Finally, sales in the other category, which is primarily our pharma partnering business, totaled $92 million. As expected, sales declined 14% resulting from a large customer electing to self-manufacture products that were previously contracted and manufactured by Baxter.

    最後,其他類別(主要為我們的製藥合作夥伴業務)銷售額合計 9,200 萬美元。如預期,銷售下滑 14%,原因是一家大型客戶選擇自行生產先前由百特承攬並製造的產品。

  • Turning to renal, global Renal sales totaled $898 million, up 5%, and we're pleased to see growth accelerate within this business. Performance in the quarter benefited from low double-digit growth in our US Peritoneal Dialysis business, as we built on the momentum from the recent launch of our new AMIA PD Cycler. The launch is trending better than our expectations, with more than 500 AMIA cyclers sold and more than 100 patients in treatment.

    談到腎臟業務,全球腎臟業務銷售額合計8.98億美元,成長5%,我們很高興看到該業務的成長正在加速。本季表現受惠於我們美國腹膜透析(PD)業務的低雙位數成長,因為我們延續了近期推出全新 AMIA PD Cycler 所帶來的動能。此次上市的表現優於我們預期,已售出超過500台 AMIA cycler,且已有超過100名病患正在接受治療。

  • The feedback we've received from clinicians and patients has been overwhelmingly positive, particularly with respect to the benefits associated with our Sharesource, two-way remote connectivity platform. We look forward to continuing to expand this launch and increasing the adoption of home therapies in the US.

    我們從臨床醫師與病患收到的回饋極為正面,特別是針對我們 Sharesource 雙向遠端連線平台所帶來的相關效益。我們期待持續擴大此次上市規模,並提升美國居家治療的採用率。

  • A standout from the quarter was global growth of nearly 20% of our acute business, driven by increased adoption of extracorporeal therapies, including Baxter's Continuous Renal Replacement Therapy for acute kidney injuries. In addition to underlying market growth, Baxter's CRRT business continues to gain market share globally. And in Chronic Hemodialysis, we experienced low single-digit growth, a positive reversal from the trend we experienced last year.

    本季的一大亮點是我們急性業務在全球接近20%的成長,主要由體外治療採用率提升所帶動,其中包括 Baxter 針對急性腎損傷的連續性腎臟替代治療(CRRT)。除了市場本身的成長外,Baxter 的 CRRT 業務也持續在全球提升市占率。而在慢性血液透析方面,我們實現了低個位數成長,較去年所見的趨勢出現正向反轉。

  • With good momentum from our first-quarter performance, the Baxter team is looking forward to our upcoming Investor Conference on May 9 in New York. We've recently completed deep-dive portfolio analysis across all businesses, which has informed us how we must channel our investments moving forward. We're well positioned to leverage our greatest opportunities, and prepare to re-tool where necessary.

    在第一季表現帶來良好動能之下,Baxter 團隊也期待即將於5月9日在紐約舉行的投資人會議。我們近期已完成針對所有業務的深度投資組合分析,這讓我們更清楚未來必須如何配置投資。我們已具備良好定位以掌握最大機會,並在必要之處做好重新調整的準備。

  • I would also point out that we will be hosting an innovation fair prior to the start of the formal presentation, showcasing our exciting new product pipeline. I look forward to seeing you -- many of you on the 9th.

    我也要指出,我們將在正式簡報開始前舉辦創新展,展示我們令人振奮的新產品研發管線。我期待在9日與各位見面——其中許多位。

  • With that, I will pass it to Jay for more details on the financials and updated outlook for 2016, then we'll have some time at the end for questions. Jay?

    接下來,我把時間交給 Jay,請他提供更多財務細節以及2016年的最新展望,之後我們會在最後留一些時間回答問題。Jay?

  • - CFO

    - CFO

  • Thanks, Joe, and good morning, everyone.

    謝謝你,Joe,各位早安。

  • As Joe mentioned, we're pleased with our first-quarter results. Operational sales growth of 4% came in at the high end of our guidance range; and including foreign exchange, sales declined 1%. Walking through the rest of the P&L, adjusted gross margin of 42.3% compared favorably to our expectations, and was driven by a positive sales mix, improved pricing, and a lower negative impact from foreign exchange.

    如 Joe 所提,我們對第一季的結果感到滿意。營運銷售成長4%,落在我們指引區間的高端;若包含匯率影響,銷售則下滑1%。接著看損益表其餘項目,調整後毛利率為42.3%,優於我們預期,主要受惠於有利的銷售組合、定價改善,以及匯率帶來的負面影響較小。

  • Adjusted SG&A totaled $620 million and decreased 17% on a reported basis. On a constant-currency basis, adjusted SG&A declined 13%, reflecting our ongoing focus on controlling spending and rebasing our cost structure. SG&A also benefited from lower pension expenses and TSA income from Baxalta of approximately $25 million in the quarter.

    調整後銷售、一般及行政費用(SG&A)合計6.20億美元,以報告基礎計算下降17%。以固定匯率計算,調整後 SG&A 下降13%,反映我們持續聚焦於控管支出並重塑成本結構。SG&A 亦受惠於較低的退休金費用,以及本季來自 Baxalta 的 TSA 收入約2,500萬美元。

  • Adjusted R&D spending in the quarter of $136 million declined 5% versus the prior year. On a constant-currency basis, adjusted R&D spend declined 2%, as we continued to balance investments in key programs to support future growth, while reducing infrastructure-related expenses. Adjusted operating margin in the quarter was 10.5%, and compared favorably to our expectations, driven by the positive gross margin and the operating savings I just referenced.

    本季調整後研發(R&D)支出為1.36億美元,較去年同期下降5%。以固定匯率計算,調整後研發支出下降2%;我們在降低基礎設施相關費用的同時,仍持續在關鍵計畫上維持投資以支持未來成長。本季調整後營業利益率為10.5%,優於我們預期,主要由前述較佳的毛利率以及營運節省所帶動。

  • Interest expense was $28 million in the first quarter. During the quarter, Baxter retired approximately $3.7 billion of gross debt through the utilization of a portion of our retained Baxalta equity and two debt-for-equity exchanges. Following these exchanges, the Company's gross debt now totals approximately $3.4 billion, and our net debt totals approximately $1.15 billion.

    第一季利息費用為2,800萬美元。本季期間,Baxter 透過動用部分保留的 Baxalta 股權,以及兩筆以債換股交易,償還約37億美元的總負債。在完成這些交換後,公司總負債目前約為34億美元,淨負債約為11.5億美元。

  • At the end of the quarter, Baxter held 30.5 million Baxalta shares, and we intend to utilize this remaining equity through a contribution to our US qualified pension plan and an equity-for-equity exchange, which was launched last week. We expect to complete utilization of all remaining Baxalta shares during the second quarter.

    截至本季末,Baxter 持有3,050萬股 Baxalta 股票;我們計畫透過對美國合格退休金計畫的出資,以及一項以股換股交易(上週已啟動)來運用剩餘股權。我們預期將在第二季完成所有剩餘 Baxalta 股票的運用。

  • Other income totaled $27 million, and included a foreign exchange gain on balance sheet positions of approximately $10 million and dividend income of approximately $10 million associated with our Baxalta equity stake. The adjusted tax rate was 19.8% for the quarter.

    其他收益合計2,700萬美元,其中包括資產負債表部位的匯兌收益約1,000萬美元,以及與我們持有的 Baxalta 股權相關的股利收入約1,000萬美元。本季調整後有效稅率為19.8%。

  • And as previously mentioned, adjusted earnings of $0.36 per diluted share exceeded our guidance of $0.28 to $0.30 per share. To decompose this favorability, it was driven by $0.04 of operational strength, $0.02 of benefit from other income, and a lower foreign exchange headwind, which contributed approximately $0.01 relative to original expectations.

    此外,如先前所提,調整後每股稀釋盈餘0.36美元,超過我們每股0.28至0.30美元的指引。拆解這項優於預期的因素,主要來自0.04美元的營運表現強勁、0.02美元的其他收益貢獻,以及匯率逆風較小,相較原先預期約貢獻0.01美元。

  • Let me conclude my comments this morning by providing an update on our outlook for 2016. Starting with sales on a constant-currency basis, we now expect 2016 full-year sales for Baxter to increase approximately 3%. And after adjusting for the US cyclophosphamide impact, we expect underlying growth of approximately 4%.

    最後,我以更新我們對2016年的展望來結束今天早上的說明。先從以固定匯率計算的銷售來看,我們目前預期 Baxter 2016年全年銷售將成長約3%。若再調整美國 cyclophosphamide 的影響,我們預期基本成長約4%。

  • On a reported basis, including the impact of foreign exchange, we expect sales to increase approximately 1%. We expect growth in the Hospital Products business of approximately 3%, or approximately 5% excluding US cyclophosphamide. Within the Hospital Products franchises, we now expect sales growth of high-single digits for fluid systems, driven by the continued strength in the US business.

    以報告基礎計算(包含匯率影響),我們預期銷售將成長約1%。我們預期醫院產品(Hospital Products)業務成長約3%,若排除美國 cyclophosphamide,則約成長5%。在醫院產品各產品線中,我們目前預期輸液系統(fluid systems)銷售將達高個位數成長,主要由美國業務持續強勁所帶動。

  • For the integrated pharmacy solutions franchise, we now expect sales to decline low-single digits, including the impact of US cyclophosphamide. Our full-year sales forecast for cyclophosphamide of $180 million remains unchanged, and is based on the assumption that two additional competitors enter the market in 2016, the first by mid-year, and the second during the latter part of 2016. After adjusting for cyclo, sales are expected to increase low-single digits.

    就整合藥局解決方案(integrated pharmacy solutions)產品線而言,我們目前預期銷售將呈低個位數下滑,包含美國 cyclophosphamide 的影響。我們對 cyclophosphamide 全年1.80億美元的銷售預測維持不變,並假設2016年將有另外兩家競爭者進入市場:第一家在年中前,第二家在2016年後段。若排除 cyclo 的影響,銷售預期將呈低個位數成長。

  • Within the surgical care franchise, we now anticipate sales to grow 1% to 2%, reflecting the softness we experienced in the first quarter. The growth trajectory for this category is expected to improve as we build upon new indications and geographic expansions. And finally for the Hospital Products business, we expect the other category to increase 6% to 7%.

    在外科照護(surgical care)產品線方面,我們目前預期銷售成長1%至2%,反映第一季所見的疲弱。隨著我們在新適應症與地理擴張上持續推進,預期此類別的成長軌跡將改善。最後,就醫院產品業務而言,我們預期其他類別將成長6%至7%。

  • For the Renal business, we continue to expect full-year sales to increase approximately 3%, driven by continued growth in our PD and acute businesses, and a stabilization in our in-center HD business.

    在腎臟業務方面,我們仍預期全年銷售將成長約3%,主要由腹膜透析(PD)與急性業務持續成長,以及院內血液透析(in-center HD)業務趨於穩定所帶動。

  • Moving down the P&L, we now expect an operating margin of approximately 11.5%, a 50-basis-point improvement versus our original guidance, reflecting favorable sales mix, disciplined management of expenses, and a lower headwind from foreign exchange. We expect interest expense to total approximately $80 million. For 2016, we expect other income of approximately $35 million.

    往下看損益表,我們目前預期營業利益率約為11.5%,較原先指引提高50個基點,反映有利的銷售組合、費用的紀律性管理,以及匯率逆風較小。我們預期利息費用合計約8,000萬美元。2016年我們預期其他收益約3,500萬美元。

  • For the year, we now expect an average adjusted tax rate of approximately 20.5%; this represents an increase from our original guidance, and is driven by incremental strength we're observing within our US business. For 2016, we anticipate an average share count of approximately 545 million shares. Based on these factors, we now expect 2016 adjusted earnings, excluding special items, of $1.59 to $1.67 per diluted share, as compared to our original guidance of $1.46 to $1.54 per diluted share.

    全年而言,我們目前預期平均調整後有效稅率約為20.5%;這較原先指引上調,主要因我們觀察到美國業務額外的強勁表現。2016年我們預期平均流通股數約為5.45億股。基於上述因素,我們目前預期2016年調整後盈餘(不含特殊項目)為每股稀釋盈餘1.59至1.67美元,相較於原先指引每股稀釋盈餘1.46至1.54美元。

  • Finally, for the year, we expect operating cash flow to now exceed $1.4 billion. We expect CapEx of approximately $900 million, which results in more than $500 million in free cash flow.

    最後,就全年而言,我們預期營運現金流如今將超過14億美元。我們預期資本支出(CapEx)約為9億美元,因此自由現金流將超過5億美元。

  • Specific to the second quarter of 2016, we expect sales growth, excluding the impact of foreign currency, to increase approximately 4%. At current foreign exchange rates, we expect reported sales to improve approximately 2%, and we expect adjusted earnings, excluding special items, of $0.38 to $0.40 per diluted share.

    就2016年第二季而言,我們預期在排除外幣影響後,銷售成長將增加約4%。以目前匯率計算,我們預期報告銷售額將改善約2%,並預期調整後盈餘(不含特殊項目)為每股稀釋後0.38至0.40美元。

  • With that, we can now open up the call for Q&A.

    接下來,我們現在可以開放電話會議進入問答環節。

  • Operator

    Operator

  • We will now being the question-and-answer session.

    我們現在開始問答時段。

  • (Operator Instructions)

    (接線員指示)

  • I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter international website for 60 days at www.baxter.com.

    提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供為期60天的數位重播,網址為www.baxter.com。

  • Mike Weinstein, JPMorgan.

    Mike Weinstein,摩根大通(JPMorgan)。

  • - Analyst

    - Analyst

  • So first question, the strength in the Fluid Systems business in the US, could you maybe try and break that out between the pump business and the medication delivery piece?

    第一個問題,美國輸液系統(Fluid Systems)業務表現強勁,能否請你嘗試把其中的成長拆分一下,分別來自幫浦業務以及藥物輸送(medication delivery)這一塊?

  • - CFO

    - CFO

  • Sure. The -- we did report a very solid first-quarter in Fluid Systems, with approximately 28% growth, and really, there were a number of drivers of that. We are seeing continued strength in Infusion Systems, which is growing north of 30%. A lot of that has to do with pump placements, or pump sales, I should say, along with the attendant sets. But having said all of that, we also had a very solid quarter in IV therapies benefiting from both volume and pricing. So in short, I think it's a combination of factors that led to the solid performance.

    當然。我們確實在輸液系統第一季繳出非常穩健的表現,成長約28%,背後其實有多項驅動因素。我們看到輸注系統(Infusion Systems)持續強勁,成長超過30%。其中很大一部分來自幫浦的裝機量,或我應該說幫浦銷售,以及隨附的耗材組件(sets)。不過即便如此,我們在靜脈注射(IV)治療方面也有非常穩健的一季,同時受惠於量與價。總之,我認為是多項因素的組合,帶來了這樣的強勁表現。

  • - Analyst

    - Analyst

  • And maybe can you do the same for the US Dialysis business? Could you just talk a little bit about the difference between the underlying PD business and the other businesses?

    那美國透析(Dialysis)業務也能用同樣方式說明一下嗎?能否談談腹膜透析(PD)本業與其他業務之間的差異?

  • - CFO

    - CFO

  • Yes. Overall Renal in the United States in the quarter grew approximately 8%, and we did see even faster growth in the PD business. As Joe mentioned in his prepared remarks, we're off to a great start with AMIA. It's a fabulous innovative, new product for us. It's been very well received, so that's one of the factors. But I think beyond that, the -- we are seeing volume and price growth in this important area and we're pleased with PD performance, which really drives the lion's share of the growth in the quarter.

    可以。本季美國腎臟(Renal)整體成長約8%,而我們在腹膜透析(PD)業務看到更快的成長。如Joe在事先準備的發言中提到的,我們的AMIA開局非常好。這對我們而言是一項極具創新、非常出色的新產品。市場反應非常正面,因此這是其中一個因素。此外,我們也在這個重要領域看到量與價的成長;我們對PD的表現感到滿意,而PD確實貢獻了本季成長的大部分。

  • - VP of IR

    - VP of IR

  • The other piece, Mike, was the acute business which we had very strong growth as well in the quarter.

    另外一塊,Mike,是急性照護(acute)業務,本季我們也有非常強勁的成長。

  • - Analyst

    - Analyst

  • Okay, and then one last follow-up. I'll let some others jump in. The cash flow improvement is obviously important and impressive. Can you just talk a little about the plans to reign in CapEx spending, where you stand with that? Are you still at $900 million for this year? Without getting ahead of us with the analyst meeting upcoming can you just talk about where you are in trying to bring the overall CapEx? Thanks.

    好的,最後再追問一個問題。我讓其他人也能加入提問。現金流的改善顯然很重要,也令人印象深刻。能否談談你們抑制資本支出(CapEx)的計畫,以及目前進展如何?今年仍然是9億美元嗎?在不搶先透露即將召開的分析師會議內容的前提下,能否談談你們目前在降低整體CapEx方面的進度?謝謝。

  • - CFO

    - CFO

  • Sure. Look, the -- I think both Joe and I would very quickly acknowledge that 9% of sales for a Company of our nature is too high. There are elements that we have to consider as we think about the Baxter business, but there is a clear opportunity for us over our long-range plan horizon to improve CapEx spending and to reduce it to a number that is below the 9%.

    當然。我想Joe和我都會很快承認,對我們這類型的公司而言,資本支出占銷售額9%確實偏高。在思考Baxter業務時,有一些要素需要納入考量,但很明顯,在我們長期計畫的期間內,CapEx支出有清楚的改善空間,我們可以把它降到低於9%的水準。

  • One thing I would point out, Mike, that we didn't really discuss in detail on the fourth quarter call, is when we were meeting with you all in May, we highlighted $900 million on average for CapEx over the long-range plan. But we did say that the early years would be above the $900 million, implying a number closer to $950 million in the first year of the plan.

    Mike,我想補充一點:我們在第四季電話會議並未詳細討論的是,當我們在5月與各位會面時,我們強調在長期計畫期間,CapEx平均為9億美元。但我們也提到,計畫初期幾年會高於9億美元,意味著在計畫第一年會更接近9.5億美元。

  • But we were very pleased with some of the zero-based activity that we did on the CapEx budget to reduce CapEx spending to start the year, and then as we move forward, this is going to be a continued area of focus for us and our full intent is to drive this down over the plan.

    不過,我們對於在CapEx預算上所做的零基礎(zero-based)活動感到非常滿意,這讓我們在年初就能降低CapEx支出;而隨著我們持續推進,這將會是我們持續聚焦的領域,我們的完整意圖是在計畫期間把它逐步降下來。

  • - Chairman and CEO

    - Chairman and CEO

  • Just to complement Jay's answer, Mike, it's not only the zero budget that we did, but also using innovation to replace large capital spending programs that we have. We're looking forward to talk to guys -- folks next week about point of care and this is one of the ways to reduce large capital spending, primarily for the PD business.

    補充Jay的回答,Mike,不只是我們做了零基礎預算(zero budget),我們也在運用創新來取代我們原本的一些大型資本支出計畫。我們期待下週與各位——各位朋友——談到床邊照護(point of care),而這是降低大型資本支出的方式之一,主要是針對PD業務。

  • - Analyst

    - Analyst

  • Perfect. Thank you Joe.

    太好了。謝謝你,Joe。

  • - CFO

    - CFO

  • Thanks Mike.

    謝謝你,Mike。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    David Roman,高盛(Goldman Sachs)。

  • - Analyst

    - Analyst

  • I wanted to start on the Surgical Care business. In your guidance, you've contemplated an acceleration throughout the year from the negative 2% up to the 1% to 2%. Could you maybe just help us understand how much of the drag in the business is coming from discontinuation of non-core product lines versus any other factors that may be negatively influencing that business and then what specifically drives that turnaround expected throughout the year?

    我想先從外科照護(Surgical Care)業務談起。在你們的指引中,你們預期全年會逐步加速,從負2%提升到1%到2%。能否協助我們理解,該業務的拖累有多少來自於停止非核心產品線,還是有其他因素也在負面影響該業務?另外,全年預期的回升具體是由什麼驅動?

  • - Chairman and CEO

    - Chairman and CEO

  • David, good morning. The Surgical Care when you get towards the second half of the year, the comps will help that business because we're anniversarying some of the negative trends in that business.

    David,早安。外科照護業務到了下半年,因為我們將迎來較有利的比較基期(comps),會對該業務有所幫助,因為我們會跨過(anniversary)該業務先前的一些負面趨勢。

  • I would like to take the opportunity to make the point that this business has two very distinctive areas. One is our hemostatic sealant, which are doing well. We need to do a better job in the international market and plans are in place for us to accelerate that, with more indications and more focused by a couple organizational changes we are going to be undertaking. But more so is to highlight, there a couple categories in that biosurgery business -- of businesses that were purchased a few years ago that are really laggards and businesses that probably don't fit in our portfolio, very small product lines but they are the ones which are dragging the comp on this business.

    我也想藉此機會指出,這項業務有兩個非常不同的領域。其一是我們的止血封合劑(hemostatic sealant),表現良好。我們需要在國際市場做得更好,相關計畫已就位,將透過更多適應症,以及我們即將推動的幾項組織調整來更聚焦、加速推進。但更重要的是要強調,在該生物外科(biosurgery)業務中,有幾個幾年前收購的品類——表現確實落後,且可能不太符合我們的產品組合;它們是非常小的產品線,但正是這些產品線拖累了該業務的比較基期表現。

  • So I want to just reassure our investors that we have a significant amount of focus in this technology. Our base business, FLOSEAL, TISSEEL, COSEAL, those are great products and doing very well. And we're looking at a couple of those laggards and see what we're going to do with them.

    因此我想向投資人保證,我們對這項技術投入了大量心力。我們的核心業務——FLOSEAL、TISSEEL、COSEAL——都是很棒的產品,且表現非常好。我們也正在檢視其中幾個落後項目,看看要如何處理。

  • - Analyst

    - Analyst

  • Okay and then maybe just a follow-up. In your prepared remarks Joe, you brought up that you had renegotiated all of your GPO contracts, I think in reference to the two parts of the Fluid Systems business. Can you maybe just put that into perspective for us? What does that mean in terms of the growth rates of these franchises that the renegotiated contracts provide greater visibility and sustainability of growth. Are there price escalators in there? How should we think about those, just in -- with some context around the overall business performance?

    好的,再追問一個問題。Joe,在你事先準備的發言中,你提到你們已重新談判所有GPO合約,我想你是針對輸液系統業務的兩個部分在說。能否幫我們把這件事放在脈絡中理解?就這些事業群的成長率而言,重新談判的合約是否帶來更高的可見度與成長的可持續性?合約中是否包含價格調升條款(price escalators)?就整體業務表現而言,我們應該如何看待這些合約?

  • - Chairman and CEO

    - Chairman and CEO

  • David, I cannot comment on the particulars of the contract. I just have to underscore the fact that we're very happy with the signing of our latest contract with HealthTrust. It's a great opportunity for the Company. We are market leaders in IV Fluid Systems and we're going to continue to be the leader in this market, by providing enough capacity for the marketplace.

    David,我無法評論合約的具體細節。我只能強調,我們對與HealthTrust簽署最新合約感到非常滿意。這對公司而言是很好的機會。我們是IV輸液系統市場的領導者,並將透過為市場提供足夠產能,持續保持在這個市場的領導地位。

  • We're being very smart about how to optimize capacity for all -- from all of our North American plants to make sure that we have enough capacity for the US market and we'll not disappoint our customers. This is part of signing the contract; there's a cycle between three and five years that we always have.

    我們正以非常精明的方式來最佳化產能配置——涵蓋我們所有北美工廠——以確保我們有足夠的產能供應美國市場,並且不會讓客戶失望。這是簽訂合約的一部分;我們一向都有一個介於三到五年的週期。

  • And our team here in the US, Brik Eyre and Scott Luce have done a superb job, really working with the GPOs and having them see how much of a value Baxter, as a partner, is. So this is -- but I cannot get into the pricing and arrangements and volume that we have in these contracts.

    而我們在美國的團隊——Brik Eyre 和 Scott Luce——做得非常出色,確實與各個 GPO 密切合作,讓他們看到 Baxter 作為合作夥伴所能帶來的價值有多大。所以這件事——但我無法談及這些合約中的定價、安排以及我們的量。

  • - Analyst

    - Analyst

  • Understood. Thank you very much.

    了解。非常感謝。

  • Operator

    Operator

  • David Lewis, Morgan Stanley.

    David Lewis,Morgan Stanley。

  • - Analyst

    - Analyst

  • Maybe one for Jay and then Joe, maybe a two-part strategic question for you. So Jay, I mean for us, to stand out in the quarter obviously was SG&A and I guess if we update for the quarter, your target of 11.5% for the year looks very achievable. Is there a reason why the cost controls unit, down 13% constant currency in the first quarter, won't hold throughout the variety of the year because it seems like if you build on this SG&A momentum, 11.5% looks conservative to us.

    也許先問 Jay 一題,接著再問 Joe——可能是給你的一個兩段式策略問題。所以 Jay,我是說,對我們而言,本季最顯眼的顯然是 SG&A;而且如果以本季來更新,你們全年 11.5% 的目標看起來非常可達成。有什麼原因使得第一季以固定匯率計算下降 13% 的成本控管,不會在今年其餘期間維持嗎?因為看起來如果延續這股 SG&A 的動能,11.5% 對我們來說似乎偏保守。

  • - CFO

    - CFO

  • Yes. David, maybe I decompose the SG&A performance in the first quarter, and then talk about the annualization of that. There are really four main elements that contribute to the $100 million decline, constant currency, year over year, in SG&A. One is TSAs of approximately $25 million; one is pension of approximately $20 million; and then there are two other elements which I refer to as some of the operational controls that we put in place; restructuring of $25 million; and spend controls of approximately $25 million.

    是的。David,也許我先拆解第一季 SG&A 的表現,然後再談談其年度化的影響。以固定匯率計算,SG&A 年對年下降 1 億美元,主要有四個構成要素。第一是 TSA 約 2,500 萬美元;第二是退休金約 2,000 萬美元;另外兩項我歸類為我們所採取的一些營運控管:重組約 2,500 萬美元;以及支出控管約 2,500 萬美元。

  • It's clear we're very proud of the progress that we've made on spending and I think the first quarter is clear evidence of that, but as we move to the latter part of the year, there's a couple things to be mindful of. First, the TSA income, we started recording this in the second half of last year so that benefit on a year-over-year basis goes away in the second half of the year.

    很明顯,我們對在支出方面取得的進展感到非常自豪,而第一季就是很清楚的證據;但隨著進入今年後半段,有幾點需要留意。第一,TSA 收入我們是從去年下半年開始入帳,因此到了今年下半年,年對年的比較基期效益就會消失。

  • And then the second comment is, with respect to restructuring and spending, we did have some benefit in the latter part of last year, as we started to implement controls very quickly after the spin-off. And so some of those benefits, it's not appropriate to annualize that performances as we move forward.

    第二點是,關於重組與支出方面,我們在去年後半段確實也有一些效益,因為在分拆後我們很快就開始導入控管措施。因此,隨著往後推進,並不適合把那些表現直接年化。

  • But it's safe to say, cost is a clear focus for us. I think the organization has taken this mandate and really, we are going after this aggressively. We're pleased with the progress and the first quarter is evidence of that.

    但可以肯定地說,成本是我們明確的重點。我認為組織已經接受這項要求,而且我們確實正積極推進。我們對進展感到滿意,而第一季就是證明。

  • - Analyst

    - Analyst

  • Okay. Very helpful. And then Joe, you're obviously having some early operational success here, specifically on margins. So I wonder, kind of two-part question. The first is, have your thoughts surround pursuing sort of larger M&A this year changed in light of slightly better revenue and operating margin trends?

    好的。非常有幫助。接著 Joe,你們顯然在營運上已經取得一些早期成果,特別是在毛利率/利潤率方面。所以我想問一個大概兩段式的問題。第一,在營收與營業利益率趨勢略有改善的情況下,你對今年追求較大型的併購(M&A)的想法是否有所改變?

  • And the second kind of question, somewhat related, is your prior management seemed to be de-emphasizing generic injectables but my sense is this management seems to be re-emphasizing generic injectables. So, one, larger M&A this year, and number two, in that broader medical management businesses, is generic injectables more of a focus for this team than it was the prior team? Thank you.

    第二個問題也有點相關:你們前一任管理團隊似乎淡化了學名注射劑,但我的感覺是這一任管理團隊似乎重新強調學名注射劑。所以,第一,今年是否會做較大型的併購;第二,在更廣泛的醫療管理業務中,學名注射劑對這個團隊而言是否比前一個團隊更受重視?謝謝。

  • - Chairman and CEO

    - Chairman and CEO

  • David, this is a clear area of focus for us. And we talk about M&A and I always say M&A is opportunistic. But transformative M&A is not in the cards, as we speak right now. So we're looking at strengthening our current core businesses and by doing it, we're going to go into adjacencies, so why is injectable generics a good area of focus?

    David,這是我們明確的重點領域。談到併購,我總是說併購是機會導向的。但就目前而言,變革性(transformative)的併購並不在規劃之中。因此我們會著眼於強化現有核心業務;而在此過程中,我們也會延伸到相鄰領域。那麼,為什麼學名注射劑是一個值得聚焦的領域?

  • We have a tremendous technology, GALAXY, in-house. We have a good program. We have several molecules for the next three to four years to come; they are in the pipeline and we are going to accelerate them as much as we can, as those need to be approved by the FDA in terms of technology. We do a great job on that. So logical extension of that would be to go in an area that strengthens those core competencies.

    我們內部擁有非常強的技術——GALAXY。我們有一個很好的計畫。未來三到四年我們有數個分子(產品)在研發管線中;我們會盡可能加速推進,當然這些仍需要在技術層面取得 FDA 的核准。我們在這方面做得很好。因此,合乎邏輯的延伸,就是進入能夠強化這些核心能力的領域。

  • Now, I cannot speak from prior -- no, about the prior management's strategic decisions. But when I look at this, I see there's a natural migration of our business. Now, the competencies to manage a business like this are slightly different and we're going to make sure that we have that in-house, or we're going to acquire [debt] to be able to be even more successful.

    至於前一任——不,我無法評論前一任管理團隊的策略決策。但當我看這件事時,我看到的是我們業務的自然遷移。當然,管理這類業務所需的能力略有不同;我們會確保這些能力在內部具備,或者我們會透過併購取得相關能力,以便更成功。

  • But this is an area of tremendous attractiveness to -- for us and I want to make sure that we are focused on that. But with all that said, the opportunistic nature of acquisitions will drive how we're going to approach this market.

    但這對我們而言是一個極具吸引力的領域,我希望確保我們聚焦於此。不過話說回來,併購的機會性本質將決定我們會如何切入這個市場。

  • - Analyst

    - Analyst

  • Okay. Very clear. Thank you so much.

    好的。非常清楚。非常感謝。

  • Operator

    Operator

  • Bob Hopkins, Bank of America.

    Bob Hopkins,美國銀行。

  • - Analyst

    - Analyst

  • Can you hear me okay?

    你們聽得到我嗎?

  • - Chairman and CEO

    - Chairman and CEO

  • Yes, we can. Good morning, Bob.

    是的,我們聽得到。早安,Bob。

  • - Analyst

    - Analyst

  • Good morning, Joe. Thank you very much for taking the question. And congrats on the good early start. So two questions. One, first for Jay or for Joe, on the Renal side, you had a really good growth quarter here this quarter. And so I guess I'm a little surprised that you're not taking the guidance up for Renal or at least I don't think I heard that. So can you just talk about the Renal growth in the quarter and why you don't think you'll see better than 3% growth over the course of the rest of this year?

    早安,Joe。非常感謝讓我提問。也恭喜你們一開始就有不錯的表現。我有兩個問題。第一個先問 Jay 或 Joe:在腎臟(Renal)業務方面,你們這一季的成長表現非常好。所以我有點驚訝你們沒有上調腎臟業務的指引,至少我不覺得我有聽到。能否談談本季腎臟業務的成長,以及為什麼你們認為今年剩餘期間不會看到高於 3% 的成長?

  • - CFO

    - CFO

  • Yes, I mean, look, overall, we were definitely pleased with the overall performance in Renal in the quarter. And I think of particular note, the acute business, as Joe mentioned in his prepared remarks, a standout quarter where we continue to be very excited about adoption there. We also had a very solid PD quarter as well. But one quarter doesn't a year make and so for us, we're mindful. We have a reasonable forecast in place for the remaining part of the year.

    是的,我是說,整體來看,我們對本季腎臟業務的整體表現確實感到滿意。而特別值得一提的是急性(acute)業務,正如 Joe 在事先準備的發言中提到的,這是一個突出的季度,我們對那邊的採用率持續感到非常振奮。我們的腹膜透析(PD)本季表現也相當穩健。但一個季度不代表一整年,因此我們仍保持審慎。我們對今年剩餘期間已建立一個合理的預測。

  • And we do have some tougher comps, particularly in the fourth quarter where in the fourth quarter of 2015, we had a very strong performance in the Renal business, so that's one where I think there's some tougher comps, and we'll continue to watch this. But as we look at the long-range plan that we've shared, the acceleration in the Renal business is a very important component of our long-term success. So I can tell you that the first quarter was one that was definitely pleasing to us.

    而且我們確實會面臨一些較嚴苛的比較基期,特別是在第四季;因為 2015 年第四季腎臟業務表現非常強勁,所以那裡的比較基期會更具挑戰,我們也會持續觀察。但就我們已分享的長期計畫而言,加速腎臟業務的成長是我們長期成功非常重要的一環。因此我可以告訴你,第一季確實讓我們感到相當欣慰。

  • - Analyst

    - Analyst

  • Okay and then -- all right, because I just want to make sure that it wasn't something that falls off in the back half or some unanticipated hurdles that you're -- that you want us to be aware of. And so for the second question, for Joe, just to follow-up on the previous question about generic injectables, just curious, as you look around the world, are there a wide range of assets available in that area? I just want to -- I'm just trying to have a better understanding of how much opportunity you think is out there in the world of generic injectables? Are there a lot of assets for you to look at?

    好的,然後——好,因為我只是想確認這不是那種在後半段會掉下來的事情,或是一些你們——你們希望我們留意的、未預期的障礙。那第二個問題給 Joe,延續前一題關於學名注射劑的問題,我只是好奇,當你放眼全球時,那個領域是否有相當廣泛的資產可供選擇?我只是想——我只是想更了解你認為在學名注射劑的世界裡,外部機會到底有多大?你們有很多資產可以評估嗎?

  • - Chairman and CEO

    - Chairman and CEO

  • Bob, for me, it's not about a number of assets, but the quality of the assets. And also what kind of APIs you're looking to participate. So we are refining the strategy to make sure that we don't have -- we're not out there generic -- easy to make APIs and things that are small. We're looking for high-quality opportunities, partnerships, different-to-manufacture APIs, create a little bit of differentiation for us.

    Bob,對我而言,重點不在於資產的數量,而在於資產的品質。以及你想參與的是哪一類 API(原料藥)。所以我們正在精煉策略,以確保我們不會——不會在外面做那種學名——容易製造、規模小的 API 之類的東西。我們在尋找高品質的機會、合作夥伴關係、較難製造的 API,為我們創造一些差異化。

  • We don't mind to go into the more common APIs but you have to have a construct where your business has some barriers for entry in areas of technology and know-how of manufacturing, so we're looking at the whole spectrum of business. So again, it's not about the quantity of targets but the quality of targets.

    我們不介意切入較常見的 API,但你必須有一個架構,讓你的業務在技術與製造專業知識上具備一些進入障礙,因此我們是在看整個業務光譜。所以再說一次,重點不在於目標的數量,而在於目標的品質。

  • - Analyst

    - Analyst

  • Great. Thanks very much.

    很好。非常感謝。

  • - Chairman and CEO

    - Chairman and CEO

  • You're welcome.

    不客氣。

  • Operator

    Operator

  • Larry Keusch, Raymond James.

    Larry Keusch,Raymond James。

  • - Analyst

    - Analyst

  • Joe, unless I missed it, I didn't really hear much of an update on the emerging markets performance for the quarter. So if you could sort of spend a couple moments just walking us through sort of how things are progressing in those emerging markets?

    Joe,除非我漏聽了,我沒有真正聽到太多關於本季新興市場表現的更新。所以如果你能花一點時間,帶我們走一遍新興市場那邊的進展情況?

  • - Chairman and CEO

    - Chairman and CEO

  • Sure. Emerging markets are doing well. We are very happy with the performance in Latin America. Like many companies you know, we have in China, seen an overall decline of growth rates. If you equalize for a Renal adjustment that we had in China, our growth rates you should be seeing towards the end of the year are close to 9% to 10%, okay?

    當然。新興市場表現良好。我們對拉丁美洲的表現非常滿意。如同許多公司一樣,你知道,我們在中國看到整體成長率下滑。如果把我們在中國做過的一次性 Renal(腎臟)調整因素排除掉,你在今年年底應該會看到我們的成長率接近 9% 到 10%,好嗎?

  • So our emerging markets is a healthy business. We, right now, are focusing in what we call the singles and doubles opportunities and we just established our -- we repurposed our R&D center, which is a global center in China, now to be China for China. Also very interested in the RTS, our renal clinics in South America, where we have some expansion opportunities there.

    所以我們的新興市場是一個健康的業務。我們目前聚焦在我們所謂的「一壘安打與二壘安打」機會,而且我們剛建立了我們——我們重新定位了我們的研發中心;那原本是中國的全球中心,現在改為「中國為中國」。另外我們也對 RTS(腎臟治療服務),也就是我們在南美的腎臟診所非常有興趣,因為那裡有一些擴張機會。

  • So our emerging markets is doing well, but we want more from it. We're not -- we're satisfied but we're not happy. We're happy but not satisfied, the other way around. We're happy but not satisfied with the performance, and we have some good opportunities ahead of us and we're going to be investing, specifically in areas such as China, some parts of Southeast Asia. There's also selective markets in Latin America. As currency weakens in some countries in Latin America offers an opportunity for potential acquisitions there at a reasonable price with a good return on investment.

    所以我們的新興市場表現不錯,但我們希望它能貢獻更多。我們不——我們滿意但不開心。我們很開心但不滿意,反過來說。我們對表現感到開心但不滿足,而且前方有一些很好的機會;我們也會投資,特別是在中國、東南亞的部分地區。拉丁美洲也有一些選擇性的市場。由於拉丁美洲某些國家的貨幣走弱,這提供了一個以合理價格進行潛在併購、並取得良好投資報酬的機會。

  • - Analyst

    - Analyst

  • Okay, and did you mention what the emerging markets growth was for the quarter?

    好的,那你有提到本季新興市場的成長是多少嗎?

  • - VP of IR

    - VP of IR

  • It was about 3% in the quarter.

    本季大約是 3%。

  • - Analyst

    - Analyst

  • Okay, perfect. And then Joe, just one other I guess sort of strategic tactical question. There's this thought out there that connectivity between devices and software between the pharmacy, the nursing station, the patient room is becoming more important, certainly up at the C-suite level. I'm just curious if, A, you do think that's a trend that will continue to increase? And maybe just spend a moment on how you guys think you are positioned there? And are you looking at both organic and inorganic opportunities there?

    好的,完美。然後 Joe,還有一個我想算是策略與戰術層面的問題。外界有一種看法是,裝置與軟體之間的連結——在藥局、護理站、病房之間——正變得更重要,尤其是在高階管理層(C-suite)層級。我只是好奇,A,你是否認為這會是一個持續增強的趨勢?以及能否花一點時間談談你們在這方面的定位如何?你們是否同時在看有機與無機的機會?

  • - Chairman and CEO

    - Chairman and CEO

  • It is a trend we'll continue [in our ability] to integrate the EMRs with general floor and ICU, connectivity and connect to patient data with libraries and [trial] libraries; and these are very important. The importance is not proportional to the adoption. There is a need for the adoption is not as clear path and immediate as one may make you believe.

    這是一個會持續的趨勢,[就我們的能力而言],能把 EMR(電子病歷)與一般病房與 ICU 整合,做連線與連接到病患資料,搭配藥物資料庫與[試驗]資料庫;這些都非常重要。其重要性並不與採用程度成正比。確實有採用的需求,但採用的路徑並不像有些人讓你以為的那樣清晰且立即。

  • So from our perspective, we have a significant effort in connectivity, wired and wireless and we have new -- two new versions of our pumps coming up in the next three years but we also are working diligently on a global platform that we're going to probably have more news in about six months down the road. But we have a significant effort. It's a great opportunity for us and as we continue to gain market share in our infusion systems, we will see us coming up with new pump versions that will enable that feature.

    所以從我們的角度,我們在有線與無線連線方面投入了相當大的努力;而且我們在未來三年內會推出——兩個新版的幫浦。但我們也正積極打造一個全球平台,我們大概在六個月後會有更多消息。總之我們投入很大。

  • Enabling of the feature doesn't mean that the adoption is going to be there. It's just to make sure that the hospital, or the hospital system, has the ability to connect with the EMR. Not everyone is ready, and -- but we will be ready, as our customers become more diligent about using this feature.

    能支援這項功能並不代表採用就一定會到位。這只是為了確保醫院或醫院體系具備與 EMR 連接的能力。不是每個人都準備好了——但我們會準備好,當我們的客戶更積極地使用這項功能時。

  • I just want to underscore the fact that our AMIA and CLARIA PD cyclers, both of them operate with a very sophisticated, cloud-based system for communication between clinician and patients. So we're already there. We have the technology and we see the future of Baxter connectivity is enabling our Sharesource technology for also infusion pumps and other devices that may be needed, including our Home Hemodialysis System, our VIVIA program.

    我想強調的是,我們的 AMIA 與 CLARIA PD 透析機(cycler),兩者都透過非常先進的雲端系統運作,用於臨床人員與病患之間的溝通。所以我們其實已經到位了。我們具備技術,也看到 Baxter 連線化的未來,是把我們的 Sharesource 技術延伸到輸注幫浦以及其他可能需要的裝置,包括我們的居家血液透析系統、我們的 VIVIA 計畫。

  • - Analyst

    - Analyst

  • Okay, great. Very helpful. Thank you.

    好的,很好。非常有幫助。謝謝。

  • Operator

    Operator

  • Matt Miksic, UBS.

    Matt Miksic,UBS。

  • - Analyst

    - Analyst

  • Thanks for taking the questions. I have a follow-up, if I could, on the Renal business to -- in particular, we -- I think, we all on the call, and investors following the Company understand the profitability opportunity, margin opportunity for pump. As you place the pumps and win more business and win more share back and drive more consumables, there's a -- I think it -- we perceive, anyway, an opportunity to take up margins in that business over time. We'd love to understand how maybe some of the same dynamics could play out for Renal, what you see there in terms of improving margins over time. There's new product cycles or consumables or some geographic, just trends would be very, very helpful and then I have one follow-up.

    謝謝讓我提問。如果可以的話,我想就腎臟(Renal)業務追問一下——特別是,我想我們在電話會議上的所有人,以及關注公司的投資人,都理解幫浦在獲利能力、毛利率上的機會。當你們布建幫浦、贏得更多業務、把市占拿回來並帶動更多耗材時——我們的看法是——那個業務的毛利率有機會隨時間提升。我們很想了解,類似的動態是否也可能在腎臟業務上發生;你們如何看待那邊毛利率隨時間改善的空間。不論是新產品週期、耗材、或某些地理區域的趨勢,任何資訊都會非常有幫助;然後我還有一個追問。

  • - Chairman and CEO

    - Chairman and CEO

  • From my perspective, we think that there's upside potential in the margins for Renal and they are different areas. First of all, you saw the performance of the in-center HD business this quarter and that's the result of the stabilization of our dialyzer business, primarily in Europe. And as we have new technology coming about Terranova, we will, hopefully, we'll be able to see that trend being steady. The -- so you have the natural momentum of that.

    從我的角度來看,我們認為腎臟業務的毛利率有上行潛力,而且來源在不同面向。首先,你看到本季院內 HD(血液透析)業務的表現,那是我們透析器(dialyzer)業務趨於穩定的結果,主要是在歐洲。隨著 Terranova 等新技術推出,我們希望能看到這個趨勢保持穩定。所以你會有那種自然的動能。

  • The second part is access to the patient. In selective markets in the world, Baxter will make an attempt to connect direct with the patients. I have a great example, in Canada, where the government is really into the PD business. They think PD First is a good policy, not only for the patient but also for the system in terms of reimbursement and cost for the system; 60% penetration in Canada.

    第二部分是接觸病患。在全球某些選擇性的市場,Baxter 會嘗試直接與病患建立連結。我舉一個很好的例子:在加拿大,政府非常支持 PD(腹膜透析)業務。他們認為「PD First」是一個好的政策,不僅對病患好,對整個體系在給付與成本方面也有利;加拿大的滲透率達到 60%。

  • So there are other opportunities in North America. We're not happy not accessing the patient in North America. So we will have creative ways of connecting to the patient through payers, through providers to be able to increase the penetration of PD; therefore, increasing the future margins of this business.

    因此,在北美還有其他機會。我們不滿意無法在北美接觸到病患。因此,我們將透過付款方、透過醫療服務提供者,以更具創意的方式與病患建立連結,來提高 PD 的滲透率;進而提升這項業務未來的利潤率。

  • I have to say that when we look at the chronic renal -- the acute renal business, that is a phenomenal business for the Company, where we're going to probably launch a platform in critical care based on [extra core portfolio] therapies to accelerate even further the growth of that business (multiple speakers) and improved margins.

    我必須說,當我們看慢性腎臟——急性腎臟業務時,這對公司而言是一項極具吸引力的業務;我們很可能會在重症照護領域推出一個以[extra core portfolio]療法為基礎的平台,以進一步加速該業務的成長(多位發言者)並改善利潤率。

  • - CFO

    - CFO

  • And just to add to that, as you look at the Renal margins over the last year, there's a couple other considerations, less strategic but impacting the numbers. One is, we have been investing in a number of R&D programs over the last year so VIVIA, AMIA, along with Prismax, which are three major platform developments. That are -- those run through the Renal segment's margins so that's a factor that will go away over time. Related to that, we'll have the benefit of new product launches at a premium price which will allow us to take margin up in that sense.

    另外補充一點,當你看過去一年腎臟業務的利潤率時,還有幾個其他考量,策略性較低但會影響數字。其一是,我們在過去一年投資了多項研發計畫,包括 VIVIA、AMIA,以及 Prismax,這三項都是重大的平台開發。這些——其成本會反映在腎臟事業部的利潤率中,因此這是一個會隨時間消退的因素。與此相關的是,我們也將受惠於以溢價推出的新產品上市,這將使我們在這個意義上提升利潤率。

  • And then the final point I would make, just tactically speaking, is you'll recall at our investor conference last year, we did comment that there was 150 basis points of incremental manufacturing costs that we had experienced in short term as we looked to address regulatory opportunities for us. That impacted our numbers in the second half of last year and all of 2015 and a large component of that related to the Renal business. We do expect some of these costs to sunset over time. So in addition to the strategic component that Joe walked you through, I think there are a number of tactical elements that will also support margin in this business.

    最後一點,我想從戰術層面來說,你會記得在我們去年的投資人會議上,我們確實提到,為了把握我們的法規機會,我們在短期內經歷了額外 150 個基點的製造成本增加。這影響了我們去年下半年的數字以及 2015 年全年,而其中很大一部分與腎臟業務相關。我們確實預期其中一些成本會隨時間到期消失。因此,除了 Joe 向你說明的策略面之外,我認為還有一些戰術性因素也將支撐這項業務的利潤率。

  • - Analyst

    - Analyst

  • Thanks for that. That's helpful color. On a separate topic, R&D, you said some expectations were sort of right, sitting at the right level for R&D in 2016. And I'd love to understand how you feel about that now and maybe how some of the -- your thinking strategically, whether it's hard to manufacture injectables, plays into sort of how you see that moderating or playing out over time, as part of your P&L?

    謝謝。這些補充資訊很有幫助。換個話題談研發,你提到對 2016 年研發費用的某些預期大致正確,處在合適的水準。我很想了解你現在對此的看法,以及你在策略上的一些思考——例如難以製造的注射劑——如何影響你對其隨時間調整或演變、並在損益表中呈現的看法?

  • - Chairman and CEO

    - Chairman and CEO

  • R&D is a key component for Baxter in terms of innovation and growth. And that's why we're going to be able to show you guys on May 9 our efforts. We're not going to show you everything but we're going to show you a portion of what we think the future holds for Baxter and a significant amount of R&D innovation that is coming through the pipe. So our commitment to R&D is very strong.

    研發對 Baxter 而言是創新與成長的關鍵組成。這也是為什麼我們將在 5 月 9 日向各位展示我們的努力。我們不會展示所有內容,但會展示一部分我們認為 Baxter 未來的方向,以及大量正在管線中推進的研發創新。因此,我們對研發的承諾非常強。

  • We have done and continue to do efficiency programs in R&D in terms of consolidation of sites and infrastructure. Infrastructure does not provide innovation. What provides innovation are people in the right places, developing products for unmet needs, and also applications for a specific market. And so what you see in terms of reduction in R&D is more of a realignment of resources across the globe and the right focus and the right products.

    我們已經做了、並且仍在持續推動研發效率計畫,包括據點與基礎設施的整併。基礎設施本身不會帶來創新。帶來創新的是在正確位置的人才,為未被滿足的需求開發產品,也為特定市場開發應用。因此,你看到的研發費用下降,更多是全球資源的重新配置,以及更正確的聚焦與更合適的產品。

  • We're starting to do capital allocations so we're going to see some movement in R&D. We're going to see some projects that will be slowed down and some that will be doubled down to be able to accelerate. In terms of hard-to-manufacture APIs, we have some capabilities in-house but we always have, at our disposal, the ability to partner with companies along -- across the globe and acquire companies across the globe. As you know, our balance sheet has good capacity and we'll be putting that to work for the shareholders, for the shareholders' interest and one of them is the ability to capitalize on our injectable core competencies.

    我們開始進行資本配置,因此你會看到研發方面的一些變動。我們會看到某些專案放慢,某些專案則會加碼投入以加速推進。就難以製造的 API(活性藥物成分)而言,我們內部具備部分能力,但我們也隨時可以與全球各地的公司合作,並在全球範圍內進行併購。如你所知,我們的資產負債表具備良好的承載能力,我們會把它用於股東、符合股東利益,其中之一就是能夠把握我們在注射劑方面的核心競爭力。

  • - Analyst

    - Analyst

  • Thanks so much.

    非常感謝。

  • Operator

    Operator

  • Joanne Wuensch, BMO Capital Markets.

    Joanne Wuensch,BMO Capital Markets。

  • - Analyst

    - Analyst

  • Good morning and thank you for taking the question. A big picture one and then a specific one. The big picture one, can you give us an idea of what you're seeing in the United States and outside the United States as it relates to sort of hospital volumes and in your relationship with those hospitals? Thank you.

    早安,謝謝讓我提問。我有一個宏觀問題和一個具體問題。宏觀問題是,你能否讓我們了解你在美國以及美國以外看到的情況,特別是與醫院量能(hospital volumes)以及你與這些醫院的關係相關的部分?謝謝。

  • - Chairman and CEO

    - Chairman and CEO

  • Joanne, hospital volumes in the US are healthy. We also need to do a -- decompose the growth that we have because we have been gaining market share in some of our categories, primarily Infusion Systems. So when you pull that aside, the market share aside, hospital business in the US is still healthy.

    Joanne,美國的醫院量能是健康的。我們也需要把我們的成長做——拆解一下,因為我們在某些品類一直在取得市占,主要是在輸注系統(Infusion Systems)。因此,當你把市占提升的因素先剔除後,美國的醫院業務仍然是健康的。

  • Price pressures are always there but we have much less of physician-preferred products so we don't speak from products that have high pressure on pricing coming from IDNs and GPOs. We have products that are used on every day, saving lives and sustaining lives of patients, and those products are very stable in terms of pricing, but also the volume is healthy, despite the fact that, [on top of world], we're gaining market share in many, many categories.

    價格壓力一直都在,但我們較少有醫師偏好型產品,因此我們不太會受到來自 IDN 與 GPO 對高定價壓力產品的影響。我們的產品是每天都在使用、用來救命並維持病患生命的產品;這些產品在定價上非常穩定,同時即使在[on top of world]的情況下,我們在許多、許多品類仍在提升市占,因此量能也很健康。

  • - Analyst

    - Analyst

  • And then outside the United States?

    那美國以外呢?

  • - Chairman and CEO

    - Chairman and CEO

  • Outside the United States, you see price pressures in some categories in Europe. Europe is still a low-growth business, not only for Baxter but across a large spectrum of healthcare. And we see some opportunity in Latin America and we see some opportunity in China for volume pick-up.

    在美國以外,你會在歐洲某些品類看到價格壓力。歐洲仍然是低成長的業務,不僅對 Baxter 如此,對廣泛的醫療保健領域也是如此。而我們在拉丁美洲看到一些機會,也在中國看到一些量能提升的機會。

  • - Analyst

    - Analyst

  • All right and then my specific question with VIVIA starting its US IDE, can you give us an update on how that product is doing outside the United States and the timing of when you expect it in the US? Thank you.

    好的,那我的具體問題是,隨著 VIVIA 在美國啟動 IDE,你能否更新一下該產品在美國以外的表現,以及你預期它在美國的時程?謝謝。

  • - Chairman and CEO

    - Chairman and CEO

  • VIVIA is doing well. We have several patients in Europe. It's a technology that continues to evolve. This is a very unique technology. When you compare to competitors that say that they have home therapies, they have hemodialysis therapies that are done in the home, no different than they are done in the center. Our therapy is done overnight in the home, allowing the patient full functionality during the day for working, productive life.

    VIVIA 表現良好。我們在歐洲已有數位病患。這是一項持續演進的技術。這是一項非常獨特的技術。當你與競爭對手相比,他們說自己有居家治療、在家進行血液透析治療,但其實與在中心進行並無不同。我們的治療是在家中夜間進行,讓病患白天能完全正常運作,去工作、過有生產力的生活。

  • If you think about this technology, it's complex and we keep improving its reliability and its ability to continue to perform in people's homes without a great deal of interference or intervening from clinicians. So the work in Europe is doing well; in the US, we are enrolling patients. We have one patient enrolled and we continue to enroll; we have a clinical trial. I'm -- I think we're little early to predict the end of the trial and approval in the US. We're in constant contact with the FDA. We have a good trial program in place. We will keep you guys updated as we see needed and we make some progress in terms of enrollment.

    如果你思考這項技術,它很複雜,而我們持續提升其可靠性,以及在不需要臨床人員大量干預或介入的情況下,仍能在民眾家中持續運作的能力。因此,歐洲的工作進展良好;在美國,我們正在招募病患。我們已納入一位病患,並持續招募;我們有一項臨床試驗。我——我認為現在要預測試驗結束以及在美國獲批的時間點還稍早。我們與 FDA 保持持續聯繫。我們已建立良好的試驗計畫。我們會在需要時、以及在招募進度上取得進展時,持續向各位更新。

  • - Analyst

    - Analyst

  • Terrific. Thank you so much.

    太好了。非常感謝。

  • - Chairman and CEO

    - Chairman and CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Danielle Antalffy, Leerink Partners.

    Danielle Antalffy,Leerink Partners。

  • - Analyst

    - Analyst

  • Thank you so much for taking the question. Joe or Jay, I was wondering if you could talk about full-year guidance and the drivers of improvement there? I mean, obviously, some of the 2Q outperformance flowed through, but you are raising the midpoint of the range even higher than the beat. So I wonder if you could walk us through some of the variables that are driving better guidance?

    非常感謝讓我提問。Joe 或 Jay,我想請你們談談全年指引,以及改善的驅動因素?我的意思是,很明顯第二季的優於預期有部分延續下去,但你們把區間中點上調的幅度甚至高於超預期的幅度。因此我想請你們帶我們梳理一下,是哪些變數在推動更好的指引?

  • - CFO

    - CFO

  • Great. Thanks for the question, Danielle. As we pointed out, at the beginning of the year our guidance range was $1.46 to $1.54, implying the midpoint of $1.50 per share. And we updated it to $1.59 to $1.67, with the midpoint being $1.64, so it's essentially a $0.14 improvement in terms of EPS. Contributing -- there are a number of factors that contribute to that. One is foreign exchange. There's approximately $0.06 of benefit from foreign exchange that we expect to see in the late -- in the remaining part or over the course of the year.

    很好。謝謝你的提問,Danielle。如同我們指出的,年初我們的指引區間是每股 $1.46 到 $1.54,意味著中位數為每股 $1.50。而我們已將其更新為每股 $1.59 到 $1.67,中位數為 $1.64,因此就 EPS 而言,基本上提升了 $0.14。促成這項提升——有多項因素共同推動。其中之一是外匯。我們預期外匯將帶來約 $0.06 的利多,會在今年後段——也就是今年剩餘期間或全年過程中逐步體現。

  • The second piece though, and frankly, this is the one that I think we're happiest about, relates to operational performance. Our expectation now is that operationally, we will be $0.06 better than our original expectations. And then there's a number of other puts and takes. Interest and other income related to equity gains and balance sheet gains is approximately $0.04 and that offsets tax rate and share count, which is a negative, roughly negative $0.03 or $0.04.

    第二個部分,而且坦白說,這是我認為我們最滿意的一項,與營運表現有關。我們目前的預期是,從營運面來看,將比原先預期好 $0.06。此外還有一些其他的正負因素拉鋸。與權益收益與資產負債表收益相關的利息及其他收入約為 $0.04,而這會抵消稅率與股數(這是負面因素),約為負 $0.03 或 $0.04。

  • So those are the primary drivers of the performance but I would highlight that, from our standpoint, as we think about the work that we're doing, both on the cost side on -- and the pricing and the mix side, a lot of those margin improvement efforts that we're undertaking, those are reflected in the $0.06 of operational over achievement that I highlighted.

    因此,這些是表現的主要驅動因素;但我想強調的是,從我們的角度來看,當我們思考正在推動的工作——不論是在成本端,以及在定價與產品組合端——我們所進行的許多毛利率改善措施,都反映在我剛才提到的那 $0.06 的營運超預期表現之中。

  • - Analyst

    - Analyst

  • And if I could just follow up quickly on the $0.06 of operational improvement. I mean, obviously margin is a bit better. How much of it is due to better execution on the sales side [lifting] and/or improving end user markets?

    如果我可以就這 $0.06 的營運改善再快速追問一下。我的意思是,顯然毛利率確實好一些。其中有多少是來自銷售端更好的執行(拉升)以及/或終端使用者市場的改善?

  • - CFO

    - CFO

  • I would say it's clearly a mix of components that lead to the $0.06, and there's definitely some spending controls that we expect to see as we move forward that contributes a portion. But from an end-user market strength, from a pricing and mix strength, that is probably the slight majority of the performance improvement that we expect to see over the year.

    我會說,促成這 $0.06 的因素顯然是多個組成部分的混合;而且我們預期隨著往前推進,確實會有一些支出控管,對其中一部分有所貢獻。但就終端市場的強勁、定價與產品組合的強勢而言,這大概占了我們預期全年表現改善的略多數。

  • - Analyst

    - Analyst

  • All right. Thanks. That's very helpful. Have a good day.

    好的。謝謝。這非常有幫助。祝你今天愉快。

  • Operator

    Operator

  • Rick Wise, Stifel.

    Rick Wise,Stifel。

  • - Analyst

    - Analyst

  • Joe, I'll start off with a, just a big picture question for you. I know we're going to hear a lot more about it at the analyst meeting, but maybe just share with us some of your early thoughts and your evolving thoughts in these early days. You clearly are busy. You're talking about some management changes, looking at the laggards, et cetera, but do you feel like you're sort of in the place you expected to be?

    Joe,我先從一個比較宏觀的問題開始。我知道我們會在分析師會議上聽到更多內容,但也許你可以先跟我們分享一些你在這段初期的想法,以及這些想法如何演進。你顯然很忙。你談到一些管理層變動、檢視落後者等等,但你覺得你目前大致處在你原本預期的位置嗎?

  • I'd be curious to hear how your thoughts are changing. Is there more opportunity to drive growth in OpEx than you expected? Is there more opportunity to add incrementally than you expected? Just that sort of at the margin, your early thoughts? Thanks.

    我也想了解你的想法正在如何改變。在營業費用(OpEx)方面,是否有比你原先預期更多的成長/改善空間?是否有比你原先預期更多的增量加值機會?就是在邊際上,你初期的一些想法?謝謝。

  • - Chairman and CEO

    - Chairman and CEO

  • Rick, as always, we are happy but not satisfied. So there was a lot of work being done by the Company before I got here but I think where we're focusing around a few themes. The first one is a true strategy with disciplined capital allocation. So what program is really going to make through the Company and give us the big needle movers.

    Rick,一如既往,我們感到高興但不滿足。在我來之前,公司已經做了很多工作,但我認為我們目前聚焦在幾個主題上。第一個是真正的策略,並搭配有紀律的資本配置。也就是哪些計畫真正能在公司內推進,並帶來最具影響力的關鍵驅動。

  • The other thing is to impart the organization to develop what I would call the singles and doubles, and have more of a global entrepreneurial approach to the singles and doubles so we can benefit from all of them instead of funneling everything through a very complex and centralized capital allocation process. So we're doing that. We understand the categories of investment. We understand what buckets and this is what we're going to talk to you guys next week.

    另一件事是,讓組織去發展我所稱的「一壘安打與二壘安打」(singles and doubles),並以更全球化、創業家的方式來推動這些小而確定的成果,如此我們就能從所有成果中受益,而不是把所有事情都導入一個非常複雜且高度集中的資本配置流程。所以我們正在這麼做。我們了解投資的類別。我們了解各個投資桶(buckets),而這也是我們下週要跟各位談的內容。

  • In terms of our cost opportunity, I just appointed a Chief Transformation Officer for the Company. He's been with the Company for a while, very well respected and understands the Company deeply. He reports directly to me and underneath this person, Robert Felicelli, we have all of the cross-transformation to simplify the Company, to understand our back office and how to make more effective and more efficient areas of spending.

    就成本機會而言,我剛任命了一位公司的首席轉型長(Chief Transformation Officer)。他在公司任職一段時間了,備受尊敬,且對公司有深刻理解。他直接向我匯報;在這位人士——Robert Felicelli——之下,我們將推動所有跨部門轉型工作,以簡化公司、了解我們的後勤/後台(back office),以及如何讓各項支出更有效、更有效率。

  • We're going through a -- no, we're going to talk more in depth next week, zero-based budget, zero-based spending, zero-based organization. We're going very hard at this because I think there's an opportunity to free up some real good cash and turn this back to the investors but also a bit of debt turned back into investment programs to make our Company grow faster.

    我們正在推進一個——不,我們下週會更深入說明——零基預算、零基支出、零基組織。我們會非常強力地推動,因為我認為這裡有機會釋放相當可觀的現金,回饋給投資人;同時也能把一部分用於降低負債,並把一部分轉回投資計畫,讓公司成長更快。

  • So we're --I'm excited, I think the people here have known are wonderful. We have great talent. And we're highly motivated to deliver to our shareholders and patients.

    所以我們——我很興奮,我認為這裡的人才都很棒。我們擁有優秀的人才。而且我們高度有動力,為股東與病患交出成果。

  • - Analyst

    - Analyst

  • That's great. Just a quick follow-up on a more detailed way, maybe for Jay. You talked about the early success with the AMIA cycler, and 500-plus cyclers sold to date. It -- just two-part question there. Is this upgrades to existing systems? Are these new patient starts and maybe just once again, frame the opportunity for AMIA, just a little more granular detail. Help us understand what the potential there is. Thanks so much.

    很棒。再快速追問一個更細節的問題,也許給 Jay。你提到 AMIA cycler 的早期成功,迄今已售出 500 多台 cycler。這裡有兩個問題。這些是既有系統的升級嗎?還是新病患的啟動(new patient starts)?另外也請再一次用更細的角度說明 AMIA 的機會,幫助我們理解其潛在空間。非常感謝。

  • - CFO

    - CFO

  • Sure. First of all, AMIA is a very new product from our standpoint so this is a completely new innovative product that we've put on the marketplace and because of not only the user interface, which has a high level of simplicity, but also because of the Sharesource technology that Joe referenced, there's a lot of excitement amongst treaters, patients around this, the AMIA cycler. So the receptivity for this has been great. Our PD US has been doing a great job promoting and moving this product forward.

    當然。首先,從我們的角度來看,AMIA 是一個非常新的產品;這是我們投放到市場上的全新創新產品。由於不僅使用者介面非常簡單易用,而且也因為 Joe 提到的 Sharesource 技術,治療端人員與病患對 AMIA cycler 都非常興奮。因此市場接受度非常好。我們的美國 PD 團隊在推廣並推動這項產品上做得非常出色。

  • What's happening as a result of the increased value that we're providing is there is a margin opportunity for us on this product, but what I would say is over time, we will expect to significantly migrate towards AMIA. It's -- we're focused on new patient starts as opposed to flipping existing patients. That would be too disruptive. But over time, this will be a larger part of our US business. Frankly, in the short term, it's not going to be a -- in 2016, it will not be a huge impact on our overall sales, but over the course of this long-range plan, I do expect this to feature very prominently for our Company.

    由於我們提供了更高的價值,這項產品也為我們帶來毛利率機會;但我要說的是,隨著時間推進,我們預期會大幅轉向 AMIA。我們的重點是新病患啟動,而不是把既有病患轉換過來。那會太具干擾性。但隨著時間推進,這會成為我們美國業務中更大的一部分。坦白說,短期內——在 2016 年——它不會對我們整體銷售造成很大的影響,但在這個長期計畫期間,我確實預期它將在公司中扮演非常重要的角色。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you and we have time for two more questions. Matt Keeler, Credit Suisse.

    謝謝,我們還有時間再問兩個問題。Matt Keeler,Credit Suisse。

  • - Analyst

    - Analyst

  • Thanks for taking the question. Just first on the retained stake can you remind us what the gating factor is to gaining approval to use that to fund the pension or are you still confident you'll be able to do that?

    謝謝讓我提問。首先關於保留持股(retained stake),你能否提醒我們,獲得核准以使用該持股來挹注/資助退休金(pension)的關鍵門檻因素是什麼?或者你們仍然有信心能夠做到?

  • - CFO

    - CFO

  • Yes. We are very pleased with the progress on the retained stake. This has gone, I would say, according to our plan. I think, frankly, our treasury, tax and legal teams have done just a fabulous job managing and organizing what is a highly complex process in a condensed timeframe. We've completed two major transactions. I referenced them, the equity for bank line and the equity for debt, really getting the balance sheet to the position that we needed to get to. There are two remaining transactions that need to take place. One is a pension contribution and one is an equity-for-equity exchange and we expect to be able to do both of these.

    是的。我們對保留持股的進展非常滿意。我會說,這一切都按照我們的計畫進行。坦白說,我認為我們的財務(資金)、稅務與法務團隊在緊湊的時間內,管理並組織這個高度複雜的流程,做得非常出色。我們已完成兩項重大交易。我提到過,也就是以股權換取銀行授信額度,以及以股權換取債務,確實讓資產負債表達到我們需要的位置。目前還有兩項交易需要完成。一項是退休金提撥,另一項是股權對股權的交換,我們預期兩項都能完成。

  • There is Department of Labor approval that is required as part of this, or I should say, a Department of Labor posting that is required as part of this and there's a final approval of an S-4 related to the equity-for-equity exchange and it's safe to say we're working closely with both the SEC and the Department of Labor to ensure all of these transactions can be done in a timely manner in advance of the close.

    其中需要取得勞工部的核准,或者我應該說,需要依此進行勞工部公告;此外,與股權對股權交換相關的 S-4 也需要最終核准。可以確定的是,我們正與 SEC 與勞工部密切合作,以確保所有這些交易都能在交割前及時完成。

  • - Analyst

    - Analyst

  • Thanks. That's helpful and just changing topics over to Surgical Care, you highlighted the drag from non-core biosurgicals on growth, can you just give us a sense of when you expect to start to lap the impact of that?

    謝謝。這很有幫助。接著把話題轉到 Surgical Care(外科護理)方面,你提到非核心生物外科產品對成長造成拖累;你能否讓我們了解一下,你預期何時會開始與其影響「對比基期」(lap)?

  • - Chairman and CEO

    - Chairman and CEO

  • The second half of the year. Second -- I just want to underscore, again, that our core biosurgery business sis doing very well. We have to adjust -- you know, the second half who have those products anniversarying. Those are laggard products. They are not part of our core business but they were added to the portfolio a few years ago. We just need to find a disposition for this -- the small products and they are probably detracting our sales force from an even further accelerating.

    在今年下半年。另外——我想再次強調,我們的核心生物外科業務表現非常好。我們必須調整——你知道,下半年這些產品會進入同週期比較(到達周年基期)。那些是落後產品。它們不是我們的核心業務,但幾年前被納入產品組合。我們需要為這些小型產品找到處置方式,因為它們可能讓我們的銷售團隊分心,反而無法進一步加速成長。

  • On the development side, we have HEMOPATCH. We have other things that are going on. Launches, we're going to increase our penetration outside the US by creating more indications. We have a healthy pipeline. We have a new oxidized cellulose product that is now being launched in several parts of the world including Europe. So it's a very exciting franchise that momentarily is having these issues with those two products, but as I said second half, we will be anniversary those numbers.

    在研發方面,我們有 HEMOPATCH。也還有其他項目在推進。在產品上市方面,我們將透過增加適應症來提升美國以外市場的滲透率。我們有健康的產品管線。我們有一款新的氧化纖維素產品,現正於包括歐洲在內的全球多個地區上市。所以這是一個非常令人振奮的事業部門,雖然短期內因那兩個產品而出現一些問題,但如我所說,下半年我們就會進入與那些數字對比基期的階段。

  • - Analyst

    - Analyst

  • Thanks so much.

    非常感謝。

  • Operator

    Operator

  • Josh Jennings, Cowen and Company.

    Josh Jennings,Cowen and Company。

  • - Analyst

    - Analyst

  • Thank you. I was hoping to circle back to the Integrated Pharmacy Solutions business and focus on the organic growth trajectory there. I believe you've talked about six to eight molecules being launched. You just announced that the VANCOMYCIN launched. Can you just help us frame the organic growth opportunities with these new molecules? Are these singles, doubles, triples, and just how it can offset some of the headwinds that we're expecting for cyclo over the next 18 months?

    謝謝。我想回到 Integrated Pharmacy Solutions(整合藥事解決方案)業務,並聚焦其內生成長軌跡。我記得你們談到將推出六到八個分子(產品)。你們剛宣布 VANCOMYCIN(萬古黴素)已上市。你能否協助我們理解,這些新分子帶來的內生成長機會?它們屬於單打、二壘打、三壘打那種等級嗎?以及它們如何在未來 18 個月抵消我們預期 cyclo 的一些逆風?

  • - Chairman and CEO

    - Chairman and CEO

  • We have a first phase which is about eight molecules but altogether, we have more -- much more than a dozen molecules that will come in the next three to four years, probably close to 2017, 2018. We have all: singles, doubles, triples. We have a third one coming up. I would say it's probably between a single and a double. We have a large one in about a year-and-a-half coming down the pike, so we are working very hard to offset, clearly, the cyclo effect.

    我們的第一階段大約是八個分子,但整體而言,未來三到四年還會有更多——遠超過一打的分子會推出,可能一直延伸到 2017、2018 年左右。我們各種都有:單打、二壘打、三壘打。我們還有第三個即將推出。我會說它大概介於單打與二壘打之間。大約一年半後還有一個大型產品在路上,因此我們正非常努力地工作,明確地要抵消 cyclo 的影響。

  • But I want to make sure that you understand that those are the organic products of the Company. We also will be very diligently looking for partnerships and acquisitions to supplement that business because we think there's a great deal of opportunity for the Company dialysis synergies.

    但我想確保你理解,這些都是公司自身的有機產品。我們也會非常積極地尋找合作夥伴與併購來補強該業務,因為我們認為公司在透析協同效益方面有很大的機會。

  • - Analyst

    - Analyst

  • Great, and if I could just follow up on the cyclophosphamide. I clearly understand that you expect one competitor midyear and another competitor closer to the end of the year. Do you have any deeper understanding of what has been the delay for your competitors? Through last year, only one competitor getting into the market, and then and now waiting till midyear or the end of the year for a second and third generic competitor. Sorry to ask you about competition, but just curious if you had any deeper understating about what's been the hold-up for those generic entrants. Thanks a lot.

    很好,如果我可以再追問一下 cyclophosphamide(環磷醯胺)。我清楚理解你們預期年中會有一個競爭者,年底附近還會有另一個競爭者。你們是否更深入了解競爭者延遲的原因?去年到目前為止,只有一個競爭者進入市場,而現在第二與第三個學名藥競爭者要等到年中或年底才會進來。抱歉問到競爭,但只是好奇你們是否對這些學名藥進入者被延宕的原因有更深入的理解。非常感謝。

  • - Chairman and CEO

    - Chairman and CEO

  • We are -- we know as much as you do. The Company, we put very limited resources in trying to understand every single detail about our competitors. Now it can be regulatory issues; it can be all kinds of different things, the ability to manufacture. So at this moment in time, we take advantage of no competitors in the markets. It's a good cash generator for the Company. We understand and we have forecasted the decline of this business, as we have communicated to you.

    我們——我們知道的跟你一樣多。公司在試圖了解競爭對手每一個細節方面投入的資源非常有限。可能是法規問題;也可能是各種不同因素,例如製造能力。所以在此刻,我們就把握市場上沒有競爭者的優勢。這對公司而言是很好的現金創造來源。我們也理解並已預測這項業務的下滑,正如我們已向你們溝通的。

  • If we don't see any major activity in the future, we will be very -- the first ones to tell you that the numbers are not changed or changing by how much. We're going to be very transparent with cyclophosphamide. It's not a strategic [partner] for the Company. What it is, is a good cash generator and we're going to use that cash to put that to good use, as I said, in getting into the injectables and double down, triple down in that business. But anything we know, we're going to make it very clear to you what it is, how much it affects us so there's full transparency in our earnings about this product.

    如果未來我們沒有看到任何重大動態,我們會非常——第一時間告訴你們,數字沒有改變,或改變了多少。對於環磷醯胺,我們會非常透明。它不是公司的策略性[夥伴]。它的本質是一個很好的現金產生來源,而我們會把這些現金善加運用,如我所說,用於切入注射劑領域,並在該業務加碼、再加碼。但只要我們知道任何資訊,我們都會非常清楚地告訴你們是什麼、對我們影響多大,讓我們在這個產品的獲利揭露上完全透明。

  • Operator

    Operator

  • Thank you. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for your participation.

    謝謝。各位女士、先生,今天百特國際(Baxter International)的電話會議到此結束。感謝各位的參與。